Navigation Links
Efavirenz in Medical News

Merck Cuts Price of Efavirenz for Developing Countries Again

Merck & Co has cut the price of efavirenz 600mg tablets (Stocrin) for developing countries that qualify for its access programme//, the company announced yesterday. It is the second price cut in a year, and crucially, it will make the branded version of efavirenz cheaper than a generic impor...

Brazilian President Silva Issues Compulsory License for Merck's Antiretroviral Efavirenz

Brazilian President Luiz Inacio Lula da Silva on Friday issued a compulsory license to produce a lower-cost, generic version of Merck's antiretroviral Efavirenz, the AP/Forbes reports. World Trade Organization regulations allow governments to declare a "national emergency" and issue compul...

HIV integrase inhibitor effective for patients beginning antiretroviral treatment

...reached that goal, compared with 82 percent of the efavirenz group. Half the raltegravir group reached the e...k four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encounte...t of Health and Human Services currently recommend efavirenz or a protease inhibitor, in combination with tenof...

Tools for more accurate dosage of drugs against HIV/AIDS and malaria

...om Zimbabwe with HIV/AIDS, and showed that a reduction in the daily dose of efavirenz from 600 mg to 400 mg can reduce the risk of undesired effects in those aff...effects of anti-HIV/AIDS drugs. Calculations showed that treatment in which efavirenz was combined with other pharmaceutical substances was more effective than t...

Study Supports Popular HIV Drug Regimen

...hers found that the combination of a drug known as efavirenz (also known as Sustiva) plus two NRTI drugs did a ...e-third of those who took lopinavir-ritonavir plus efavirenz -- two drugs instead of the usual three -- and in...'s a simpler treatment for patients," she said. efavirenz isn't for everyone, Riddler cautioned. "A certain ...

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

... $78 million in the same period in 2006. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S. and Canada with Gilead Sciences, Inc. -- S...

Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a p...

Brazil Government New Health Offer

...tributing free drugs and condoms in his new AIDS program angered the international drug company Merck. Merck offered to cut the price of its AIDS drug efavirenz to about $1 per pill but Temporao decided to break Merck's patent and buy a cheaper substitute from India. His blunt style is reaching beyond ...

Thailand Unfazed As US Worries Over Copyright Violations

...emporarily suspend patent protections on medicines to safeguard public health. Thailand has issued compulsory licenses for AIDS drugs Kaletra and efavirenz and popular heart disease medicine Plavix. The government plans to import generic versions of the drugs from India, but could also choose to manufactu...

Brazil Opts for Indian Drugs Bypassing Merck

...S pharmaceutical giant Merck's patent on AIDS drug efavirenz and opted for a cheaper generic alternative from ... Brazil will be able to import generic versions of efavirenz from three companies in India - and the price for ...ating with Merck for three years to bring down the efavirenz price. Lula had criticized Merck for charg...
Efavirenz in Medical Technology

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "The data presented this week demonstrate the value of...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in t...

Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008

...g studied in phase III trials, achieved an undetectable viral load (<50 HIV-1 RNA copies/mL) at week 96 compared with 71 percent of patients receiving efavirenz (EFV). Of patients receiving the 75 mg and 150 mg doses of TMC278, 72 percent and 71 percent achieved an undetectable viral load, respectively. "NNR...

Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV

...V-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs), in treatment-naive HIV-...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potenti...

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

...vantages. These include: the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen;...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

...candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieves trough levels in human...t a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; t...

IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients

...activity against established NNRTI-resistant clinical isolates. Compared to efavirenz (Sustiva(R)), the emergence of IDX899-resistant HIV-1 isolates was slower a...ted in-vitro with IDX899 were different from those selected with efavirenz. efavirenz appeared to be active against IDX899 resistant viruses and IDX899 remained ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

...of their first antiretroviral treatment regimen. efavirenz is marketed by Bristol-Myers Squibb Company (NYSE:...nd, Germany, Italy, Spain and the United Kingdom). efavirenz is commercialized by Merck & Co., Inc, through its...s-like behavior, but it could not be determined if efavirenz was the cause. Patients with serious psychiatric a...
Efavirenz in Biological News

Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults

...V-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less l...re significantly less likely than those started on efavirenz to achieve high treatment adherence." Nachega, ...erse transcriptase inhibitor such as nevirapine or efavirenz in resource limited settings. Nearly 67 percent of...
Efavirenz in Biological Technology

Monogram Announces 2008 Third Quarter Financial Results

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "Given the efficacy of existing first line treatments,...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... $82 million in the same period in 2007. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S., Canada and Europe with Gilead Sciences, ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a ...
Other Tags
(Date:12/19/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... Franklin, Ind. The top executive search firm in the ... than 900 healthcare executives into organizations. , Johnson ... providing care to the residents of Johnson County and ...
(Date:12/19/2014)... 2014 If you have ever been ... you probably wished you had an arsenal of treatments ... fibrosis, and other breathing disorders. Currently, the only proven ... triggers, but other common treatments do exist. At ... San Antonio, TX, 34 asthma educators responded to a ...
(Date:12/19/2014)... December 19, 2014 Consilium Staffing, ... the AMSUS Society for Federal Health Professionals annual ... tenens industry to military and federal healthcare providers. ... National Veterans Small Business Engagement (NVSBE) conference last ... to be a vital solution in addressing our ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... born to moms who were exposed to high levels of ... of developing autism, a U.S. study suggests. Researchers found ... 1990 and 2002, those exposed to the most air pollution ... who later developed autism. And exposure during the third trimester, ...
(Date:12/17/2014)... 17, 2014 While countless companies tempt patients ... realize the potential dangers of their purchase. Not only is ... a qualified doctor, but patients who buy hCG online are ... there is actually no real hCG present. Illegal internet hCG ... are no safety standards and may contain unknown fillers that ...
Breaking Medicine News(10 mins):Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
Other Contents